


heteroaliphatic, aryl, heteroaryl, alkylaryl, or alkylheteroaryl moiety, whereby at least one of R_E or R_F represents a cyclic or acyclic aliphatic or heteroaliphatic moiety, and wherein one or more of said cyclic or acyclic aliphatic or heteroaliphatic moieties described above is substituted with one or more phosphorus moieties having the structure:




wherein each occurrence of M is independently CV₂, -NV-, -O- or -S-, wherein each occurrence of V is independently hydrogen, OH, halogen, or aliphatic; each occurrence of Y is independently a covalent bond, -O-, -S- or N(R₁)₂, wherein R₁, for each occurrence, is independently hydrogen, aliphatic, heteroaliphatic, aryl, heteroaryl, alkylaryl, or alkylheteroaryl; each occurrence of x is independently 1 or 2; and each occurrence of R₁ is independently hydrogen, aliphatic, heteroaliphatic, aryl, heteroaryl, alkylaryl, alkylheteroaryl, a prodrug or pharmaceutically acceptable derivative.

113. The compound of claim 108 or 112, wherein [R₃] R_C is -ZR_E, wherein Z is -O-, -S-, or NR_F, wherein R_E is hydrogen, or an aliphatic, heteroaliphatic, aryl, heteroaryl, alkylaryl, or alkylheteroaryl moiety, and R_F is an aliphatic, heteroaliphatic, aryl, heteroaryl, alkylaryl, or alkylheteroaryl moiety, whereby at least one of R_E or R_F represents [an aryl, heteroaryl, alkylaryl, or alkylheteroaryl] a cyclic or acyclic aliphatic or heteroaliphatic moiety, whereby at least one of said [aryl, heteroaryl, alkylaryl, or alkylheteroaryl] cyclic or acyclic aliphatic or heteroaliphatic moieties is substituted by at least one phosphorus moiety.

2) Response to Species Election:

In response to the Species Election Requirement mailed January 10, 2002, Applicants elect the following species as exemplified on page 79 of the specification as filed (Example 34):

[Hydroxy-(3-{9-[2-(3-hydroxy-phenyl)-ethyl]-6-phenylamino-9H-purin-2-ylamino}-propyl)-phosphinoylmethyl]-phosphonic acid



As required, Applicants have provided below a listing of all of the claims readable thereon:

Claims 1, 2, 4, 5, 7, 9, 10, 11, 16, 107, 108, 109, 110, 113, 114, 115, 116, 117, 121, 122, 158, 159, 162, 165, 167, 171, 175, 176, 178, 181, 182, 183, 184, 187, and 190.

REMARKS

Applicants have amended claim 108 and 113 to include definitions for R_C (claim 108) and to amend certain typographical errors (claim 113). Specifically, claim 113 is dependent upon claims 108 and 112 which refer to compounds having aliphatic and heteroaliphatic moieties substituted with phosphorus moieties, and thus claim 113 was amended to remove reference to aryl and heteroaryl moieties, and to include the correct reference to aliphatic and heteroaliphatic moieties. Support for this amendment can be found throughout the specification, and Applicants respectfully submit that no new matter is presented with this amendment.

Applicants would like to thank the Examiner for consideration of this case, and if it is believed that a telephone conversation would help clarify any issues, or help expedite prosecution of this case, Applicants invite the Examiner to contact the undersigned at (617) 248-5216. Additionally, please charge the two (2) month extension of time from January 10, 2002 up to and including April 10, 2002, (and any additional fees that may be required) or credit any overpayment to our Deposit Account 03-1721.

Respectfully submitted,

Karoline K. M. Shair

Karoline K. M. Shair, Ph.D.

Reg. No.: 44,332

Choate, Hall & Stewart
Exchange Place
53 State Street
Boston, MA 02109
(617) 248-5000
Date: April 10, 2002
3385818_1.DOC

CERTIFICATE OF FACSIMILE TRANSMISSION
PURSUANT TO 1096 OG 30-31
I hereby certify that this paper is being
facsimile transmitted to the Assistant
Commissioner For Patents, Washington,
DC 20231
on

April 10, 2002
Kathleen H. Hogen